Abstract
A Trial of the Princess Margaret, Chicago and California Phase II Consortia
Highlights
- •Cediranib has activity in recurrent ovarian cancer
- •Expected toxicities were manageable with a dose reduction of cediranib (30 mg daily)
Purpose
Cediranib is a potent
multitargeted inhibitor of vascular endothelial growth factor receptor
(VEGFR) 1, 2 and 3. The study was initiated to evaluate the activity of
cediranib in patients (pts) with recurrent ovarian, peritoneal or
fallopian tube cancer (OC).
Methods
Eligible
pts had persistent/recurrent OC following one prior platinum-based
chemotherapy with measurable disease or progression based on Gynecologic
Cancer Inter Group CA-125 criteria. Because of toxicities observed in
the first 23 pts, the initial starting dose of oral daily (od) cediranib
was reduced from 45 mg to 30 mg. The primary endpoint was objective
response rate at 16 weeks. This study was stratified into two arms:
platinum-sensitive (PL-S) and platinum-resistant (PL-R).
Results
74
pts were enrolled; 39 were PL-S and 35 PL-R, with a median age of 58
years [31–87]. In PL-S group, 10 partial responses (PR) and stable
disease (SD) in 20 (51%) were confirmed while in the PL-R arm there were
no confirmed PR and 23 pts (66%) had SD. The main grade 3/4 toxicities
were hypertension (24%), fatigue (17%) and diarrhea (9%). The median
progression-free survival for all patients was 4.9 months [3.9-7.0], 7.2
months [4.3-9] for PL-S and 3.7 months [2.6-4.5] for PL-R group. The
median overall survival was 18.9 months (95% CI: 13.5-31.5); 27.7 months
[17.8-43.3] for PL-S and 11.9 months [8.1-18.9] for PL-R group.
Conclusion
Cediranib
shows significant activity in recurrent platinum sensitive OC. The
toxicities were expected and manageable at the dose of 30 mg od.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.